DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Pirarubicin is an investigational drug.
There have been 18 clinical trials for Pirarubicin. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2012.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Transitional Cell, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are Beijing Jishuitan Hospital, Peking University First Hospital, and Peking University People's Hospital.
There are two US patents protecting this investigational drug and twenty-eight international patents.
Recent Clinical Trials for Pirarubicin
|Combination Therapy of Anthracyclines for Children With Nephroblastoma||Shengjing Hospital||Phase 4|
|Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma||Beijing Jishuitan Hospital||Phase 2/Phase 3|
|Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma||Chinese PLA General Hospital||Phase 2/Phase 3|
Top disease conditions for Pirarubicin
Top clinical trial sponsors for Pirarubicin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pirarubicin||See Pricing||Heat shock protein 70 (hsp-70) receptor ligands||Duke University (Durham, NC)||See Pricing|
|Pirarubicin||See Pricing||Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus||Seattle Genetics, Inc. (Bothell, WA)||See Pricing|
|Pirarubicin||See Pricing||Anti-FGFR3 antibodies and methods using same||Genentech, Inc. (South San Francisco, CA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Pirarubicin||World Intellectual Property Organization (WIPO)||2015148714||2034-03-25||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|